NCT01779050View on ClinicalTrials.gov

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

PHASE2TerminatedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

December 19, 2013

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions

Breast Neoplasms

Interventions

DRUG

Doxorubicin

BIOLOGICAL

Trastuzumab

DRUG

Cyclophosphamide

DRUG

Paclitaxel

DRUG

Epirubicin

DRUG

Docetaxel

DRUG

Carboplatin

DRUG

Fluorouracil

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER